NCT05107856 2024-01-31PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesPrelude TherapeuticsPhase 1 Terminated21 enrolled
NCT00543582 2015-07-01MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaMirati Therapeutics Inc.Phase 2 Terminated23 enrolled